HPTH (1-34) HAS AN ANABOLIC EFFECT ON TRABECULAR BONE IN PATIENTS WITH CRUSH FRACTURE OSTEOPOROSIS WHEN IT STIMULATES NEW BONE-FORMATION

被引：0
|
作者：
REEVE, J [1 ]
BERNAT, M [1 ]
HESP, R [1 ]
MEUNIER, PJ [1 ]
PARSONS, JA [1 ]
SLOVIK, D [1 ]
VISMANS, J [1 ]
机构：
[1] MRC,CLIN RES CTR,HARROW HA1 3UJ,MIDDLESEX,ENGLAND
来源：
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | 1979年 / 9卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [21] Histomorphometry and microstructure of iliac trabecular bone in osteoporosis on intermittent subcutaneous administration of human PTH (1-34)
    Nakatsuka, K
    Naka, H
    Kawakami, H
    Kitatani, K
    Miki, T
    Nishizawa, Y
    Morii, H
    BONE, 2001, 28 (05) : S240 - S241
  • [22] Parathyroid hormone 1-34 and skeletal anabolic action THE USE OF PARATHYROID HORMONE IN BONE FORMATION
    Osagie-Clouard, L.
    Sanghani, A.
    Coathup, M.
    Briggs, T.
    Bostrom, M.
    Blunn, G.
    BONE & JOINT RESEARCH, 2017, 6 (01): : 14 - 21
  • [23] CA-47 KINETIC MEASUREMENTS OF BONE TURNOVER COMPARED TO BONE HISTOMORPHOMETRY IN OSTEOPOROSIS - THE INFLUENCE OF HUMAN PARATHYROID FRAGMENT (HPTH 1-34) THERAPY
    REEVE, J
    ARLOT, M
    BERNAT, M
    CHARHON, S
    EDOUARD, C
    SLOVIK, D
    VISMANS, FJFE
    MEUNIER, PJ
    METABOLIC BONE DISEASE & RELATED RESEARCH, 1981, 3 (01): : 23 - 30
  • [24] The association of serum RANKL and OPG levels with other biochemical markers of bone turnover in glucocorticoid induced osteoporosis patients treated with hPTH (1-34)
    Lane, N
    Yao, W
    Arnaud, CD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S209 - S209
  • [25] HUMAN PARATHYROID HORMONE-(1-34) PREVENTS BONE LOSS AND AUGMENTS BONE-FORMATION IN SEXUALLY MATURE OVARIECTOMIZED RATS
    LIU, CC
    KALU, DN
    JOURNAL OF BONE AND MINERAL RESEARCH, 1990, 5 (09) : 973 - 982
  • [26] INFLUENCE OF HPTH(1-34), HCT, PGE2 AND PGF2-ALPHA ON INVITRO METABOLISM OF HUMAN TRABECULAR BONE
    KECK, E
    SCHARTL, A
    WEST, TB
    VANLILIENFELDTOAL, H
    LAKOMEK, HJ
    KRUSKEMPER, HL
    ACTA ENDOCRINOLOGICA, 1983, 102 : 13 - 13
  • [27] TREATMENT OF OSTEOPOROSIS WITH PARATHYROID PEPTIDE (HPTH 1-34) AND ESTROGEN - INCREASE IN VOLUMETRIC DENSITY OF ILIAC CANCELLOUS BONE MAY DEPEND ON REDUCED TRABECULAR SPACING AS WELL AS INCREASED THICKNESS OF PACKETS OF NEWLY FORMED BONE
    BRADBEER, JN
    ARLOT, ME
    MEUNIER, PJ
    REEVE, J
    CLINICAL ENDOCRINOLOGY, 1992, 37 (03) : 282 - 289
  • [28] Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - Results from a placebo-controlled randomized trial.
    Roe, EB
    Sanchez, SD
    del Puerto, GA
    Pierini, E
    Bacchetti, P
    Cann, CE
    Arnaud, CD
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S137 - S137
  • [29] SERUM OSTEOCALCIN IN THE TREATMENT OF SENILE OSTEOPOROSIS WITH ANABOLIC-STEROIDS - FURTHER EVIDENCES FOR A NEW MARKER OF BONE-FORMATION
    CANTATORE, FP
    CARROZZO, M
    DAMORE, M
    PIPITONE, V
    CLINICAL RHEUMATOLOGY, 1986, 5 (04) : 535 - 536
  • [30] Parathyroid hormone (hPTH 1-34) and estrogen dramatically increases bone density in postmenopausal osteoporosis: A placebo-controlled randomized trial
    Roe, EB
    Cann, CF
    Sanchez, SD
    Bachetti, P
    Black, D
    Arnaud, CD
    OSTEOPOROSIS INTERNATIONAL, 2000, 11 : S196 - S197
12345